Novartis, Eli Lilly
Lilly Wants Records From People Who Took Weight-Loss Knockoffs
Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their medical records as it continues to build a case against businesses selling the compounded drugs.
The Price War in Weight-Loss Drugs Is Here
Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price tags of over $1,000 a month.
How Novartis plans to thrive without competing directly with Eli Lilly in weight loss drug market
As weight-loss treatments dominate the pharmaceutical market, Swiss drugmaker Novartis AG (SWX: NOVN) is choosing a different path. While competitors like Eli Lilly and Novo Nordisk race to capture the booming weight-loss drug market,
Health Rounds: Next generation Lilly weight-loss drug shows added heart, liver benefits
Eli Lilly's experimental next generation weight-loss drug mimics three hormones instead of just one or two and continues to show promising clinical trial results for additional health benefits, the company said.
Weight loss market: Smaller rivals muscle in on Eli Lilly and Novo Nordisk
As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up to release their own treatments, aiming to challenge the two industry leaders.
Eli Lilly Names New CFO Amid Weight-loss Drug Expansion Plan
U.S. pharmaceutical giant Eli Lilly named a new chief financial officer on Monday during a critical time for the company's exploding weight-loss drug market.
Lilly weight loss drug prevents diabetes, company says
Lilly also sells tirzepatide under the brand name Mounjaro, to treat people with diabetes, though they typically lose less weight than people without the disease. The list price of both Mounjaro and Zepbound runs about $1,000, though coupons and discounts can reduce the cost
Lilly Wants Records of People Who Took Weight-Loss Knockoffs (1)
Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their medical records for safety reasons, a move that comes as it builds a case against businesses selling the compounded drugs.
Novartis not joining the 'frenzy' of weight loss drugs, CEO says
Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.
Weight-loss drug competition heats up with growing pill market
The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk and Eli Lilly by introducing GLP-1 pills.
This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
New York Post23d
Eli Lilly slashes price of weight-loss drug Zepbound by 50% to sell in smaller doses
Eli Lilly said it has started selling single-dose vials of its uber-popular weight-loss drug Zepbound as demand soars – and the smaller doses cost 50% less than rival drugs. The more ...
GLP-1 pills are coming, and they could revolutionize weight-loss treatment
At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...
Prediction: This Will be Eli Lilly's Next Big Move.
Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...